S5-E20.1 – Drug Development Highlights from EASL Congress 2024: Resmetirom
This conversation from EASL Congress 2024 discusses some of the new research on resmetirom.
June 22, 2024
This conversation from EASL Congress 2024 discusses some of the new research on resmetirom.
Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
In two separate conversations, Global Liver Institute Founder and CEO and industry executive and consultant hepatologist Dimitar Tonev share memories of Stephen Harrison with co-hosts Jörn Schattenberg and Roger Green.
Panelists reflect on their personal memories of Stephen Harrison
Colleagues and friends Manal Abdelmalek and Naim Alkhouri join the Surfers in the first of what will be several conversations remembering our co-founder, the SLD master Stephen Harrison.
This final conversation about MASH drug development includes continued discussion of combination therapies and a discussion on NITs’ vital role in speeding the process and making it more efficient.
Sven Francque and William Alazawi join the Surfers discuss the impact of concomitant metabolic therapies like incretin agonists on MASH Drug Development.
Michael Charlton describes the impact of Rezdiffra on practices and procedures in his clinic
Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.